The chemical synthesis of relatively short segments of nucleic acids with defined chemical structure is known as oligonucleotide synthesis. The method is particularly valuable in recent laboratory practice since it allows for quick and low-cost access to custom-made oligonucleotides of the appropriate sequence. The future use of customized therapy to cure chronic illnesses is ideal because to oligonucleotide synthesis.
The global market for Oligonucleotide Synthesis Linkers was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Oligonucleotide Synthesis Linkers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide Synthesis Linkers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Oligonucleotide Synthesis Linkers was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Oligonucleotide Synthesis Linkers include Agilent Technologies, Inc, ATDBio Ltd, Bio-Synthesis Inc, BioAutomation, LGC Biosearch Technologies, Sarepta Therapeutics, Kaneka Corporation, GeneDesign, Inc and General Electric, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Synthesis Linkers, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Oligonucleotide Synthesis Linkers by region & country, by Type, and by Application.
The Oligonucleotide Synthesis Linkers market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Synthesis Linkers.
Market Segmentation
By Company
Agilent Technologies, Inc
ATDBio Ltd
Bio-Synthesis Inc
BioAutomation
LGC Biosearch Technologies
Sarepta Therapeutics
Kaneka Corporation
GeneDesign, Inc
General Electric
GenScript
Integrated DNA Technologies, Inc
NITTO DENKO CORPORATION
Thermo Fisher Scientific, Inc
TriLink BioTechnologies
Danaher
Maravai LifeSciences
Biogen
Eurofins Scientific
Merck KGaA
Huzhou Hippo Biotechnology Co., Ltd.
Segment by Type:
Single-Ended Index Connector
Double-Ended Index Connector
Segment by Application
Molecular Detection
Genetic Diagnosis
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oligonucleotide Synthesis Linkers manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Oligonucleotide Synthesis Linkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Oligonucleotide Synthesis Linkers in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Market Overview
1.1 Oligonucleotide Synthesis Linkers Product Introduction
1.2 Global Oligonucleotide Synthesis Linkers Market Size Forecast
1.2.1 Global Oligonucleotide Synthesis Linkers Sales Value (2019-2030)
1.2.2 Global Oligonucleotide Synthesis Linkers Sales Volume (2019-2030)
1.2.3 Global Oligonucleotide Synthesis Linkers Sales Price (2019-2030)
1.3 Oligonucleotide Synthesis Linkers Market Trends & Drivers
1.3.1 Oligonucleotide Synthesis Linkers Industry Trends
1.3.2 Oligonucleotide Synthesis Linkers Market Drivers & Opportunity
1.3.3 Oligonucleotide Synthesis Linkers Market Challenges
1.3.4 Oligonucleotide Synthesis Linkers Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oligonucleotide Synthesis Linkers Players Revenue Ranking (2023)
2.2 Global Oligonucleotide Synthesis Linkers Revenue by Company (2019-2024)
2.3 Global Oligonucleotide Synthesis Linkers Players Sales Volume Ranking (2023)
2.4 Global Oligonucleotide Synthesis Linkers Sales Volume by Company Players (2019-2024)
2.5 Global Oligonucleotide Synthesis Linkers Average Price by Company (2019-2024)
2.6 Key Manufacturers Oligonucleotide Synthesis Linkers Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Oligonucleotide Synthesis Linkers Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Oligonucleotide Synthesis Linkers
2.9 Oligonucleotide Synthesis Linkers Market Competitive Analysis
2.9.1 Oligonucleotide Synthesis Linkers Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Oligonucleotide Synthesis Linkers Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Synthesis Linkers as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single-Ended Index Connector
3.1.2 Double-Ended Index Connector
3.2 Global Oligonucleotide Synthesis Linkers Sales Value by Type
3.2.1 Global Oligonucleotide Synthesis Linkers Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oligonucleotide Synthesis Linkers Sales Value, by Type (2019-2030)
3.2.3 Global Oligonucleotide Synthesis Linkers Sales Value, by Type (%) (2019-2030)
3.3 Global Oligonucleotide Synthesis Linkers Sales Volume by Type
3.3.1 Global Oligonucleotide Synthesis Linkers Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Oligonucleotide Synthesis Linkers Sales Volume, by Type (2019-2030)
3.3.3 Global Oligonucleotide Synthesis Linkers Sales Volume, by Type (%) (2019-2030)
3.4 Global Oligonucleotide Synthesis Linkers Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Molecular Detection
4.1.2 Genetic Diagnosis
4.1.3 Other
4.2 Global Oligonucleotide Synthesis Linkers Sales Value by Application
4.2.1 Global Oligonucleotide Synthesis Linkers Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oligonucleotide Synthesis Linkers Sales Value, by Application (2019-2030)
4.2.3 Global Oligonucleotide Synthesis Linkers Sales Value, by Application (%) (2019-2030)
4.3 Global Oligonucleotide Synthesis Linkers Sales Volume by Application
4.3.1 Global Oligonucleotide Synthesis Linkers Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Oligonucleotide Synthesis Linkers Sales Volume, by Application (2019-2030)
4.3.3 Global Oligonucleotide Synthesis Linkers Sales Volume, by Application (%) (2019-2030)
4.4 Global Oligonucleotide Synthesis Linkers Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Oligonucleotide Synthesis Linkers Sales Value by Region
5.1.1 Global Oligonucleotide Synthesis Linkers Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oligonucleotide Synthesis Linkers Sales Value by Region (2019-2024)
5.1.3 Global Oligonucleotide Synthesis Linkers Sales Value by Region (2025-2030)
5.1.4 Global Oligonucleotide Synthesis Linkers Sales Value by Region (%), (2019-2030)
5.2 Global Oligonucleotide Synthesis Linkers Sales Volume by Region
5.2.1 Global Oligonucleotide Synthesis Linkers Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Oligonucleotide Synthesis Linkers Sales Volume by Region (2019-2024)
5.2.3 Global Oligonucleotide Synthesis Linkers Sales Volume by Region (2025-2030)
5.2.4 Global Oligonucleotide Synthesis Linkers Sales Volume by Region (%), (2019-2030)
5.3 Global Oligonucleotide Synthesis Linkers Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
5.4.2 North America Oligonucleotide Synthesis Linkers Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
5.5.2 Europe Oligonucleotide Synthesis Linkers Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
5.6.2 Asia Pacific Oligonucleotide Synthesis Linkers Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
5.7.2 South America Oligonucleotide Synthesis Linkers Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
5.8.2 Middle East & Africa Oligonucleotide Synthesis Linkers Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oligonucleotide Synthesis Linkers Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oligonucleotide Synthesis Linkers Sales Value
6.2.1 Key Countries/Regions Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.2.2 Key Countries/Regions Oligonucleotide Synthesis Linkers Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.3.2 United States Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.4.2 Europe Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.5.2 China Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.6.2 Japan Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.7.2 South Korea Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.8.2 Southeast Asia Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oligonucleotide Synthesis Linkers Sales Value, 2019-2030
6.9.2 India Oligonucleotide Synthesis Linkers Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oligonucleotide Synthesis Linkers Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Agilent Technologies, Inc
7.1.1 Agilent Technologies, Inc Company Information
7.1.2 Agilent Technologies, Inc Introduction and Business Overview
7.1.3 Agilent Technologies, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Agilent Technologies, Inc Oligonucleotide Synthesis Linkers Product Offerings
7.1.5 Agilent Technologies, Inc Recent Development
7.2 ATDBio Ltd
7.2.1 ATDBio Ltd Company Information
7.2.2 ATDBio Ltd Introduction and Business Overview
7.2.3 ATDBio Ltd Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.2.4 ATDBio Ltd Oligonucleotide Synthesis Linkers Product Offerings
7.2.5 ATDBio Ltd Recent Development
7.3 Bio-Synthesis Inc
7.3.1 Bio-Synthesis Inc Company Information
7.3.2 Bio-Synthesis Inc Introduction and Business Overview
7.3.3 Bio-Synthesis Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Bio-Synthesis Inc Oligonucleotide Synthesis Linkers Product Offerings
7.3.5 Bio-Synthesis Inc Recent Development
7.4 BioAutomation
7.4.1 BioAutomation Company Information
7.4.2 BioAutomation Introduction and Business Overview
7.4.3 BioAutomation Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.4.4 BioAutomation Oligonucleotide Synthesis Linkers Product Offerings
7.4.5 BioAutomation Recent Development
7.5 LGC Biosearch Technologies
7.5.1 LGC Biosearch Technologies Company Information
7.5.2 LGC Biosearch Technologies Introduction and Business Overview
7.5.3 LGC Biosearch Technologies Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.5.4 LGC Biosearch Technologies Oligonucleotide Synthesis Linkers Product Offerings
7.5.5 LGC Biosearch Technologies Recent Development
7.6 Sarepta Therapeutics
7.6.1 Sarepta Therapeutics Company Information
7.6.2 Sarepta Therapeutics Introduction and Business Overview
7.6.3 Sarepta Therapeutics Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Sarepta Therapeutics Oligonucleotide Synthesis Linkers Product Offerings
7.6.5 Sarepta Therapeutics Recent Development
7.7 Kaneka Corporation
7.7.1 Kaneka Corporation Company Information
7.7.2 Kaneka Corporation Introduction and Business Overview
7.7.3 Kaneka Corporation Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Kaneka Corporation Oligonucleotide Synthesis Linkers Product Offerings
7.7.5 Kaneka Corporation Recent Development
7.8 GeneDesign, Inc
7.8.1 GeneDesign, Inc Company Information
7.8.2 GeneDesign, Inc Introduction and Business Overview
7.8.3 GeneDesign, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.8.4 GeneDesign, Inc Oligonucleotide Synthesis Linkers Product Offerings
7.8.5 GeneDesign, Inc Recent Development
7.9 General Electric
7.9.1 General Electric Company Information
7.9.2 General Electric Introduction and Business Overview
7.9.3 General Electric Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.9.4 General Electric Oligonucleotide Synthesis Linkers Product Offerings
7.9.5 General Electric Recent Development
7.10 GenScript
7.10.1 GenScript Company Information
7.10.2 GenScript Introduction and Business Overview
7.10.3 GenScript Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.10.4 GenScript Oligonucleotide Synthesis Linkers Product Offerings
7.10.5 GenScript Recent Development
7.11 Integrated DNA Technologies, Inc
7.11.1 Integrated DNA Technologies, Inc Company Information
7.11.2 Integrated DNA Technologies, Inc Introduction and Business Overview
7.11.3 Integrated DNA Technologies, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Integrated DNA Technologies, Inc Oligonucleotide Synthesis Linkers Product Offerings
7.11.5 Integrated DNA Technologies, Inc Recent Development
7.12 NITTO DENKO CORPORATION
7.12.1 NITTO DENKO CORPORATION Company Information
7.12.2 NITTO DENKO CORPORATION Introduction and Business Overview
7.12.3 NITTO DENKO CORPORATION Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.12.4 NITTO DENKO CORPORATION Oligonucleotide Synthesis Linkers Product Offerings
7.12.5 NITTO DENKO CORPORATION Recent Development
7.13 Thermo Fisher Scientific, Inc
7.13.1 Thermo Fisher Scientific, Inc Company Information
7.13.2 Thermo Fisher Scientific, Inc Introduction and Business Overview
7.13.3 Thermo Fisher Scientific, Inc Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Thermo Fisher Scientific, Inc Oligonucleotide Synthesis Linkers Product Offerings
7.13.5 Thermo Fisher Scientific, Inc Recent Development
7.14 TriLink BioTechnologies
7.14.1 TriLink BioTechnologies Company Information
7.14.2 TriLink BioTechnologies Introduction and Business Overview
7.14.3 TriLink BioTechnologies Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.14.4 TriLink BioTechnologies Oligonucleotide Synthesis Linkers Product Offerings
7.14.5 TriLink BioTechnologies Recent Development
7.15 Danaher
7.15.1 Danaher Company Information
7.15.2 Danaher Introduction and Business Overview
7.15.3 Danaher Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Danaher Oligonucleotide Synthesis Linkers Product Offerings
7.15.5 Danaher Recent Development
7.16 Maravai LifeSciences
7.16.1 Maravai LifeSciences Company Information
7.16.2 Maravai LifeSciences Introduction and Business Overview
7.16.3 Maravai LifeSciences Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Maravai LifeSciences Oligonucleotide Synthesis Linkers Product Offerings
7.16.5 Maravai LifeSciences Recent Development
7.17 Biogen
7.17.1 Biogen Company Information
7.17.2 Biogen Introduction and Business Overview
7.17.3 Biogen Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Biogen Oligonucleotide Synthesis Linkers Product Offerings
7.17.5 Biogen Recent Development
7.18 Eurofins Scientific
7.18.1 Eurofins Scientific Company Information
7.18.2 Eurofins Scientific Introduction and Business Overview
7.18.3 Eurofins Scientific Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Eurofins Scientific Oligonucleotide Synthesis Linkers Product Offerings
7.18.5 Eurofins Scientific Recent Development
7.19 Merck KGaA
7.19.1 Merck KGaA Company Information
7.19.2 Merck KGaA Introduction and Business Overview
7.19.3 Merck KGaA Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.19.4 Merck KGaA Oligonucleotide Synthesis Linkers Product Offerings
7.19.5 Merck KGaA Recent Development
7.20 Huzhou Hippo Biotechnology Co., Ltd.
7.20.1 Huzhou Hippo Biotechnology Co., Ltd. Company Information
7.20.2 Huzhou Hippo Biotechnology Co., Ltd. Introduction and Business Overview
7.20.3 Huzhou Hippo Biotechnology Co., Ltd. Oligonucleotide Synthesis Linkers Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Huzhou Hippo Biotechnology Co., Ltd. Oligonucleotide Synthesis Linkers Product Offerings
7.20.5 Huzhou Hippo Biotechnology Co., Ltd. Recent Development
8 Industry Chain Analysis
8.1 Oligonucleotide Synthesis Linkers Industrial Chain
8.2 Oligonucleotide Synthesis Linkers Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oligonucleotide Synthesis Linkers Sales Model
8.5.2 Sales Channel
8.5.3 Oligonucleotide Synthesis Linkers Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Agilent Technologies, Inc
ATDBio Ltd
Bio-Synthesis Inc
BioAutomation
LGC Biosearch Technologies
Sarepta Therapeutics
Kaneka Corporation
GeneDesign, Inc
General Electric
GenScript
Integrated DNA Technologies, Inc
NITTO DENKO CORPORATION
Thermo Fisher Scientific, Inc
TriLink BioTechnologies
Danaher
Maravai LifeSciences
Biogen
Eurofins Scientific
Merck KGaA
Huzhou Hippo Biotechnology Co., Ltd.
听
听
*If Applicable.
